TY - JOUR
T1 - Improvement of cisplatin-related renal dysfunction by synthetic ghrelin
T2 - A prospective randomised phase II trial
AU - Yanagimoto, Yoshitomo
AU - Takiguchi, Shuji
AU - Miyazaki, Yasuhiro
AU - Makino, Tomoki
AU - Takahashi, Tsuyoshi
AU - Kurokawa, Yukinori
AU - Yamasaki, Makoto
AU - Miyata, Hiroshi
AU - Nakajima, Kiyokazu
AU - Hosoda, Hiroshi
AU - Kangawa, Kenji
AU - Mori, Masaki
AU - Doki, Yuichiro
PY - 2016/6/14
Y1 - 2016/6/14
N2 - Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.
AB - Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.
UR - http://www.scopus.com/inward/record.url?scp=84973121363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973121363&partnerID=8YFLogxK
U2 - 10.1038/bjc.2016.160
DO - 10.1038/bjc.2016.160
M3 - Article
C2 - 27253174
AN - SCOPUS:84973121363
SN - 0007-0920
VL - 114
SP - 1318
EP - 1325
JO - British journal of cancer
JF - British journal of cancer
IS - 12
ER -
